Acute, low-dose methamphetamine administration improves attention/information processing speed and working memory in methamphetamine-dependent individuals displaying poorer cognitive performance at baseline.
Abstinent methamphetamine (Meth) dependent individuals demonstrate poorer performance on tests sensitive to attention/information processing speed, learning and memory, and working memory when compared to non-Meth dependent individuals. The poorer performance on these tests may contribute to the morbidity associated with Meth-dependence. In light of this, we sought to determine the effects of acute, low-dose Meth administration on attention, working memory, and verbal learning and memory in 19 non-treatment seeking, Meth-dependent individuals. Participants were predominantly male (89%), Caucasian (63%), and cigarette smokers (63%). Following a four day, drug-free washout period, participants were given a single-blind intravenous infusion of saline, followed the next day by 30 mg of Meth. A battery of neurocognitive tasks was administered before and after each infusion, and performance on measures of accuracy and reaction time were compared between conditions. While acute Meth exposure did not affect test performance for the entire sample, participants who demonstrated relatively poor performance on these tests at baseline, identified using a median split on each test, showed significant improvement on measures of attention/information processing speed and working memory when administered Meth. Improved performance was seen on the following measures of working memory: choice reaction time task (p≤0.04), a 1-back task (p≤0.01), and a 2-back task (p≤0.04). In addition, those participants demonstrating high neurocognitive performance at baseline experienced similar or decreased performance following Meth exposure. These findings suggest that acute administration of Meth may temporarily improve Meth-associated neurocognitive performance in those individuals experiencing lower cognitive performance at baseline. As a result, stimulants may serve as a successful treatment for improving cognitive functioning in those Meth-dependent individuals experiencing neurocognitive impairment.
Baylor College of Medicine, Menninger Department of Psychiatry and Behavioral Sciences, Houston, TX, United States. james.mahoney@bcm.edu
James J
JJ
Mahoney
Brian J
BJ
Jackson
Ari D
AD
Kalechstein
Richard
R
De La Garza
Thomas F
TF
Newton
D000328:Adult; D019969:Amphetamine-Related Disorders / Q000188:drug therapy* / Q000523:psychology*; D001288:Attention / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007276:Injections, Intraventricular; D007858:Learning / Q000187:drug effects; D008297:Male; D008568:Memory / Q000187:drug effects; D008570:Memory, Short-Term / Q000187:drug effects; D008694:Methamphetamine / Q000008:administration & dosage*; D009483:Neuropsychological Tests; D011930:Reaction Time / Q000187:drug effects; D013997:Time Factors; D014706:Verbal Learning / Q000187:drug effects; D055815:Young Adult
D000697:Central Nervous System Stimulants; D008694:Methamphetamine